US Patent

US12042504 — Injectable fosaprepitant composition

Formulation · Assigned to Spes Pharmaceuticals Inc · Expires 2039-01-11 · 13y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable compositions of fosaprepitant or a pharmaceutically acceptable salt thereof, lacking polysorbate 80, and containing dual functional excipients.

USPTO Abstract

The present application and its embodiments teach stable compositions of fosaprepitant or a pharmaceutically acceptable salt thereof with such compositions lacking polysorbate 80 and containing dual functional excipients of hydrolysis inhibition and solubility enhancement. Further described are methods of preparation of such compositions. Among other advantages of contemplated compositions, fosaprepitant hydrolysis degradation is kept low and the compositions maintain physically and chemically stable for prolonged period.

Drugs covered by this patent

Patent Metadata

Patent number
US12042504
Jurisdiction
US
Classification
Formulation
Expires
2039-01-11
Drug substance claim
No
Drug product claim
Yes
Assignee
Spes Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.